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Key points 1	
¥! A multifaceted intervention including psycho-education, motivational interviewing, andshort 2	
message services improved medication adherence among patients aged over 65 who were 3	
undergoing coronary artery bypass graft (CABG) surgery. 4	
¥! The effects of the multifaceted intervention on medication adherence were maintained 5	
eighteen months following the intervention.  6	
¥! Quality of life and survival rates improved as a consequence of increasing medication 7	
adherence.	 	8	
5 
	
Abstract 1	
Background.Patients undergoing coronary artery bypass graft (CABG) surgery are required to 2	
take a complex regimen of medications for extended periods, and they may have negative 3	
outcomes because they struggle to adhere to this regimen. Designing effective interventions to 4	
promote medication adherence in this patient group is therefore important. 5	
Objective.The present study aimed toevaluate the long-term effects of a multifaceted 6	
intervention(psycho-education, motivational interviewing, and short message services) on 7	
medication adherence, quality of life (QoL), and mortality ratesin older patients undergoing 8	
CABG surgery. 9	
Methods.Patients aged over 65 years from 12 centers were assigned to theintervention (EXP; 10	
n=144) or treatment as usual (TAU; n=144)groups using cluster randomization at center 11	
level.Medication adherence was evaluated using Medication Adherence Rating Scale (MARS), 12	
pharmacy refill rate, and lipid profile;QoL using Short-Form36. Data were collectedat 13	
baseline;three, six, and eighteen months after intervention.Survival status was followed up at 14	
eighteen months.Multi-level regressionsand survival analyses for hazard ratio (HR) were used 15	
for analyses. 16	
Results.Compared to patientswho received TAU, theMARS, pharmacy refill rate, and lipid 17	
profile of patients in the EXP group improved six months after surgery (p<0.01)andremained so 18	
eighteen months after surgery (p<0.01). QoLalso increased among patients in the EXPgroup as 19	
compared to those who received TAU at eighteen-month post-surgery(physical component 20	
summary score p = 0.02; mental component summary score p = 0.04). HR in the EXP group 21	
compared to the TAU group was 0.38 (p=0.04).  22	
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Conclusion.The findings suggest that a multifaceted intervention can improve medication 1	
adherence in older patients undergoing CABGsurgery, with theseimprovements being 2	
maintained aftereighteen months. QoL and survival rates increased as a function ofbetter 3	
medication adherence.  4	
ClinicalTrials.gov NCT02109523   5	
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1. Introduction 1	
 Coronary artery bypass graft (CABG) surgeryis often considered to be the primary 2	
intervention forindividuals suffering from severe coronary artery disease and has been shown to 3	
increase quality of life (QoL) and life expectancy [1-3].The mortality rate during CABG surgery 4	
has declined [4-8], including among older patients,even up to 90 years or above [6,7].However, 5	
although CABG is a promising surgery for older patients with severe coronary artery disease, 6	
there are some reasons to suspect thatolder patients may have more negative outcomes after 7	
CABG surgery than younger patients[9,10]. 8	
 Patients undergoing CABG surgery are required to take a complex regimen of 9	
medications over a long period of time [9].Therefore, one reason why older patients may have 10	
more negative outcomes is that they struggle to adhere to this regimen [10].Some characteristics 11	
ofthe geriatric population, including hearing difficulties,impaired cognition, poormanual 12	
dexterity and vision, and low tolerance ofthe effects of drugs mayresult in low rates of adherence 13	
[11]. In addition, older patients undergoing CABGsurgery share some of the factors that lead to 14	
noncompliance among younger patients, such as poor education about the importance, and 15	
adverse effects of, each medication, polypharmacy (the use of four or more medications), the 16	
need to take multiple doses each day, the cost of medication, and the incorrect use of medication 17	
[12]. Because medication adherence positively influences outcomes(e.g., decreases functional 18	
disability, morbidity, and mortality) [13,14], it is important to design interventions that can 19	
improve medication adherence among older patients undergoing CABG surgery.  20	
 A meta-analysisof33 randomized controlled trials of interventions designed to improve 21	
medication adherence among older patients [15] found that the interventions incorporating 22	
psycho-education, behavioral interventions, and interventions based on the theory of planned 23	
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behavior significantly improved medication adherence (effect size, d=0.33) and knowledge about 1	
medications (d=0.48) relative to control conditions. However, the meta-analysisdefined older 2	
patients in a relatively broad way (i.e., as those older than 60 years). Hence, their results may not 3	
generalize to older populations (i.e., those aged over 65 years); especially as age has been found 4	
to influence medication adherence among people with myocardial infarction [13]. Also, none of 5	
the primary studies focused on promoting medication adherence amongolder patients undergoing 6	
CABGsurgery; therefore, more evidence is needed on interventions that can improve medication 7	
adherence for olderpatients undergoing CABG surgery. 8	
 Multifaceted interventionsseem to be an appropriate way to promote medication 9	
adherence because many factors can simultaneouslyinfluence the behavior [16,17]. For example, 10	
a prospective study found that medication counseling accompanied by planningincreased 11	
medication adherence amongpatients with a mean age of 59 years undergoing CABGsurgery 12	
[18]. However, given that older samples (e.g., those aged over 65)may have additional issues that 13	
prevent them from successfully adhering to medications (e.g., further impairments to hearing and 14	
cognition);it is possible that additional intervention components are needed to promote 15	
medication adherence among these patients. Therefore, the present research developed an 16	
intervention that consisted of psycho-education, motivational interviewing (MI) [19-21] 17	
accompanied by planning, and sending reminders via a short message service (SMS)[22] in an 18	
effort to increase medication adherence amongpatients aged over 65 undergoing CABG surgery. 19	
The intervention alsoencouraged the patientsÕ family to help because family members may 20	
influence medication adherence amongpatients undergoing CABG surgery [23], especially in 21	
Eastern cultureswhere family relationships are particularly valued [24].  22	
9 
	
 In addition to identifying effective ways to promote medication adherence, it is also 1	
important to understand how and why interventions are effective Ð i.e., to identify the underlying 2	
mechanisms. Multifaceted interventions likely change relevant cognitions and self-regulatory 3	
processes that, in turn, lead to changes in the outcomes of interest (namely, medication 4	
adherence). Based on extant research, it seems likely that patientsÕ intentions, behavioral 5	
automaticity, levels of action and coping planning, perceived behavioral control, self-monitoring, 6	
beliefs about medicines, and illness perceptions could all potentially mediate the effects of the 7	
intervention on outcomes (i.e., medication adherence, QoL, and mortality rate). Intentions reflect 8	
the direction and strength of a personÕs motivation to perform the relevant behavior (such as 9	
medication adherence in our study) [18]. Behavioral automaticity reflects whether a patient 10	
engages in a behavior (e.g., taking medication) relatively automatically; that is quickly, easily, 11	
and without the need for conscious thought[25]. Action and coping planning reflect the extent to 12	
which patients haveidentified obstacles that may prevent them from engaging in a behavior and 13	
made plans specifying how they plan to deal with these;perceived behavioral control reflects 14	
how competent someone feels in their ability to perform a behavior [26]. Self-monitoring 15	
indicates whether someone regularly reflects on and monitors his/her behavior and/or the 16	
outcomes of their behavior [27,28]. Beliefs about medicines refer to a patientÕs beliefs about the 17	
necessity and adverse effects of the medication they take [29], and illness perceptions indicate 18	
how a patient understands his/her illness [30]. A number of theoretical frameworks suggest that 19	
these social cognitions and self-regulatory processes affect the likelihood that a person will 20	
engage in a behavior [31-34]. Therefore, we considered that these factors could potentially 21	
mediate the impact of the multifaceted intervention on behavior (i.e., medication adherence). 22	
Moreover, because QoL and mortality rate are further outcomes of medication adherence 23	
10 
	
[13,14], medication adherenceshould mediate the effect of the intervention on QoL and mortality 1	
rates. 2	
1.1 Objectives 3	
 The present study aimedto evaluate the long-term effects of a multifaceted intervention 4	
(including psycho-education, motivational interviewing, and a short message service[SMS]) on 5	
medication adherence (primary outcome), and QoL and mortality rates (secondary outcomes) in 6	
older patients undergoing CABG surgery.In addition, we measured a number of relevant social 7	
cognitions (e.g., strength of intentions to take medication) and self-regulatory processes (e.g., 8	
action and coping planning) as potential mediators of the effects of the intervention on 9	
medication adherence. 10	
2. Methods 11	
This trial was registered at ClinicalTrials.gov with the registration number 12	
NCT02109523. 13	
2.1 Design and study population 14	
 The study adopted an open-label, researcher-blind, randomized controlled design, with 15	
two arms.Specifically, one arm received multifaceted intervention (see Section 2.3 Intervention 16	
for more details); another received treatment as usual (see Section 2.5 Treatment as Usual for 17	
more details). Patientswere recruited frommultiple centers across Iran (5 academic centers in 18	
Tehran, 2 in Qazvin and Ahvaz each,1 in Semnan, Zanjan, andTabriz each). Inclusion criteria 19	
were that patients:(a) be aged 65 years or above, (b) had undergoneCABG surgery, (c)had the 20	
ability to read and write Persian/Farsi, (d)provided informed consent to participate, and (e) had 21	
access to a mobile phone. Exclusion criteria were that patients:(a) had already usedDosette boxes 22	
(or similar) to improve medication adherence, (b) were currently enrolled in another clinical trial, 23	
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(c) suffered from significant dysphasia, severe kidney disease (creatinine clearance < 30 ml/min), 1	
oxygen-dependent chronic obstructive pulmonary disease, active hepatitis, significant hepatic 2	
failure, and/ora prior peptic ulcer (platelet count < 150×10
9
), (d) were having concomitant 3	
surgery,(e) suffered from a severe cognitive impairment (i.e., Mini Mental Status Examination 4	
MMSE score of< 20, (f) had had a myocardial infarction within 48hours of surgery, (g) were 5	
allergic to aspirin, (h) abused alcohol or narcotics, (i) reportedongoing bleeding, (j) had a 6	
terminal condition or were deemed unlikely to survive until six-month follow-up, (k) were not 7	
being responsible for their own medication, and (l) the CABG was conducted as an emergency 8	
surgery.Patients with poor prognosis (n=2) and those who had CABG as an emergency surgery 9	
(n=3) were excluded to increase the likelihood that we were able to measure relevant outcomes 10	
at eighteen months. Patients requiring emergency or urgent CABG are at higher risk than those 11	
undergoing CABG electively, and emergency CABG is typically carried out if serious 12	
complications develop after a heart attack (e.g., shock, life-threatening abnormalities of the heart 13	
rhythm, or rupture of heart tissues), thus there is an increased risk of mortality among such 14	
patients [9].  15	
 Five trained general practitioners assessed each participant with respect to 16	
theaforementionedinclusion and exclusion criteria, after which all eligible patientswereinvited to 17	
participate in a group information session in a seminar room in their respective hospitals. In this 18	
session, the principal investigator and a surgeon explained the aims of the study and answered 19	
any questions that the patients had. Interested patients were then asked to sign a consent form 20	
and were assigned a unique study identification (ID) number. Following this, patients 21	
completedbaselinemeasures (n=288patients completed this assessment). The measures were 22	
repeated at six, twelve, and eighteen months after the intervention.Ethics approval was obtained 23	
12 
	
from the review committees of the different centers and partner institutions who approved the 1	
trial (QUMS.REC.1394.2).The study was conducted in accordance with the Ottawa Statement, 2	
the Helsinki Declaration, and Good Clinical Practice. 3	
2.2 Randomization and blinding 4	
 In order to minimize contamination and maximize the efficiency with which the 5	
intervention was delivered, centers were chosen as the units of randomization. Specifically, the 6	
centers were randomly assigned to either the intervention (EXP) or the treatment as usual (TAU) 7	
groups by an independent statistician following a 1:1 scheme using a computer generated list of 8	
random numbers. Six centers were assigned to the EXP group and six centers were assigned to 9	
the TAUgroup. Figure 1 shows the flow of patients through the study. 10	
(Insert Figure 1 here) 11	
 The sample size needed to detect any effects of the intervention was calculated based on 12	
the primary outcome measure (self-reported medication adherence). It was estimated that 144 13	
patients would be needed in each group to detect an effect (difference) = 1 score, with 90% 14	
power and a significance level of 5%, assuming a standard deviation of 1.9 in both groups, 15	
design effect of 1.8, and 5% loss at follow up. Exactly 144 patients were therefore allocated to 16	
each group as suggested by the sample size calculation.  17	
All researchers responsible for measuring outcomes as well as statisticians were blinded 18	
to the group allocation. However, it was not possible for patients to be blind to group allocation 19	
because of the use of behavioral interventions. Therefore, objective measures of medication 20	
adherence such as total cholesterol, high-density lipoprotein (HDL) and low-density lipoprotein 21	
(LDL) concentrations were also evaluated, alongside self-reported rates of adherence to reduce 22	
the likelihood of demand effects. 23	
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2.3 Intervention 1	
 Patients in the EXP group received a multifaceted interventionthat included:(a) psycho-2	
education, (b) motivational interviewing (MI), and (c) sending reminders via SMS. The 3	
intervention began the first week after the patients were discharged. 4	
2.3.1 Psycho-education 5	
 Patientsin the EXP group participated in three weekly sessions accompanied by at least 6	
one family member with whom they had a close relationship (e.g., their father, mother, spouse, 7	
brother or sister).The psycho-education component of the intervention was delivered by 8	
cardiovascular nurses. The contents and topics of psycho-education were discussed and 9	
preselected by cardiovascular nurses as well as cardiologists. The content of the psycho-10	
education was the same for all patients and delivered orally.Each session lasted for one hour and 11	
the main purpose was to provide information aboutcoronary artery disease andways of coping 12	
with the disease (e.g., the potential barriers to, and concerns about, coping with the disease). In 13	
addition, patientsÕ experiences during previous visits, a list of previous medications and their 14	
effects and side-effects, the reasons for previous medication non-adherence, as well as the 15	
reactions and communication between the family members about the patientsÕ symptomswere 16	
discussed. 17	
2.3.2 Motivational interviewing (MI) 18	
 The patients in the EXP group attended five weekly sessions of MI that each lasted 19	
around 50 minutes. All sessions were held in a quiet, private, and comfortable setting inside the 20	
hospitals. The sessions were delivered by five trained and registered psychologists with 21	
experience (more than 100 hours) in moderating MI sessions. These psychologistsusedseveral 22	
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MI techniques that could potentially help the patients to increase their medication adherence, 1	
including open-ended questions, rolling with resistance, agenda setting, eliciting self-2	
motivational statements, change talk, and affirmations. Following this, the psychologists 3	
highlighted factors that might interfere with the patientsÕ plans to take their medication (also 4	
called: action planning) andasked the patients to anticipate situations in which they might 5	
struggle to take their medicationalong with possible strategies that they might use to overcome 6	
these barriers (also called:coping planning) [18]. At the end of the session, patients were asked to 7	
put the form on which they had written their plan(s) in a place that was easily visible and 8	
accessible for them. Detailed information on the procedure for the MI sessions is provided in 9	
Electronic Supplementary Material Table S1.  10	
2.3.3 Reminders via SMS 11	
 Four reminders were sent to patients on a monthly basis via text messages. The content of 12	
the messages differed each month as follows: (1) The only way to improve your health is regular 13	
adherence to your medications; (2) Regular adherence to your medications will greatly help your 14	
recovery process and improve your health; (3) The most important factor for preventing a heart 15	
attack is that you take your medication regularly; and (4) Carefully considerwhich medication 16	
you take on a daily basis. 17	
2.4 MI integrity/fidelity 18	
 In order to assess the quality and integrity of MI, all sessions were audiotaped.To 19	
evaluate integrity, the Motivational Interviewing Treatment Integrity (MITI) scale 3.1.1 was used 20	
[35]. The MITI is a widely used measure of competences in MI. It normallymakes use of a 20-21	
minute segment of each MI session and evaluates this segment based on global scores and 22	
15 
	
behavior counts (two components of the MITI) to capture treatment fidelity.Twenty percent of 1	
the audiotaped sessions were selected randomly for evaluation by an independent/external 2	
coder.The global scores comprise five global ratings including evocation, collaboration, 3	
autonomy/support, direction, and empathy. The behavior counts include providing information, 4	
asking open- and closed-ended questions, providing simple and complex reflections, and making 5	
other statements categorized as MI adherent or not. In addition to the abovementioned 6	
components, five summary scores (i.e., each domain of the global ratings: evocation, 7	
collaboration, autonomy/support, direction, and empathy)were also computed to provide a more 8	
concise measure of competence. 9	
 Electronic Supplementary Material Table S2 provides the global measures, behavior 10	
counts, and summary scores of the MITI. All of the facilitators who delivered the MI were 11	
competent, according to this measure. Specifically, the means of global measures were between 12	
3.61 and 4.59, and the mean percentage of facilitators who were MI adherent was 93.12. Most 13	
means were slightly below competency, but above beginning proficiency.  14	
2.5 Treatment as Usual  15	
 Patients allocated to thetreatment as usual(TAU)group received the advice commonly 16	
given by surgeons oncoronary artery diseaseand the CABG procedure, along with information on 17	
the importance of healthy diet and nutrition. Patients in the TAU group were further informed 18	
about the importance of medication adherence and encouraged to regularly take their 19	
medications, as well as being reminded of the negative consequences of nonadherence. Providing 20	
this information tookapproximately 30 minutesand took place in a room in the respective 21	
hospitals before the patientsÕ discharge.  22	
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2.6 Outcomes  1	
 All outcomes were measured at baseline (before the intervention), andthensix, twelve, 2	
and eighteen months post-surgery. Detailed information on each of the measures is described 3	
below. The measures of intentions, action and coping planning, perceived behavioral control, and 4	
self-monitoring were based on similar measures used in previous research [18,25-30], but were 5	
adapted so as to be relevant for Iranian patients undergoing CABG. 6	
2.6.1 Medication Adherence Rating Scale  7	
 The Medication Adherence Rating Scale (MARS)is a short self-report scale measuring 8	
medication adherence that consists of 5 items which patients are asked to respond to on a 5-point 9	
Likert scale (from 1: always to 5: never) [36]. Scores range from 5 to 25 with higher 10	
scoresindicating better medication adherence [18]. The Persian version of the MARSin the 11	
current studyproved internally consistent (CronbachÕs α=0.89).  12	
2.6.2 Pharmacy refill rate 13	
 The pharmacy refill rate was defined as the number of days on which medications were 14	
dispensed to the patient during the study period, divided by the total number of days in the study 15	
period. This figure was then multiplied by 100 to give a percentage. All related information was 16	
collected monthly from 22 pharmacies in 6 cities and included the total number of pills 17	
prescribed along with the dates of each prescription. We assessed the cardiovascular medication 18	
adjusted for inpatient days and medication refills prior to enrollment date as well as information 19	
registered at six and twelve monthsÕ follow-up on change in prescriptions. 20	
2.6.3 Lipid profile  21	
17 
	
 Serum lipid profiles were determined for all patients by taking 5ml of venous blood after 1	
overnight fasting. Total cholesterol (TC), triglycerides (TG) and high-density lipoprotein-2	
cholesterol (HDL-C) concentrations were determined by the enzymatic colorimetric method. 3	
Low-density lipoprotein-cholesterol (LDL-C) concentration, as well as serum TC, TG and HDL-4	
C concentrations were calculated using the Friedewald formula.  5	
2.6.4 Intentions 6	
 Patients completed a short (5-item) questionnaire designedto measure their intentions to 7	
take medication, with items (e.g., ÒI intend to regularly take medicine in the futureÓ) 8	
beingresponded to on a 5-point Likert-type scale (from 1: completely disagree to 5: completely 9	
agree) [18].The measure of intentions showedsatisfactory internal consistency in this study 10	
(CronbachÕs α=0.90).
 
11	
2.6.5 Self-report Behavioral Automaticity Index 12	
 The Self-report Behavioral Automaticity Index (SRBAI)measures the extent to which a 13	
particular behavior (e.g., taking medication) is automatic for an individual [25]. The 14	
SRBAIconsists of four statements that begin with ÒBehavior X is somethingÉÓ, followed 15	
bydifferent descriptions, such as ÒI do automaticallyÓ; ÒI do without having to consciously 16	
rememberÓ; ÒI do without thinkingÓ; ÒI start doing before I realize I am doing itÓ. Patients are 17	
asked torate the extent to which they agree with each of the statements on a 5-point Likert-type 18	
scale (from 1: disagree to 5: agree), and items were summed. The Persian version of the SRBAI 19	
was found to be highly reliable in this study (CronbachÕs α = 0.91).  20	
2.6.6 Action and coping planning  21	
18 
	
 Four items were used to measure action planning: ÒI have made a detailed plan regarding 1	
when / where / how often /how to take medication. Another four items were used to measure 2	
coping planning. Patients were provided withthe stem: ÒI have made a detailed plan regardingÉÓ 3	
followed by four different endings: ÒÉwhat to do if something interferesÓ; ÒÉwhat to do if I 4	
forgot itÓ; ÒÉhow to motivate myself if I donÕt feel like itÓ; ÒÉhow to prevent being distractedÓ 5	
[26].All items were rated on a 5-point Likert-type scale (1: completely disagree to 5: completely 6	
agree) and both the measures of action planning (CronbachÕs α=0.93) and coping planning 7	
(CronbachÕs α=0.91) proved internally consistent.
 
8	
2.6.7 Perceived behavioral control 9	
 Perceived behavioral control (PBC)was measured with four items, to which patients 10	
responded on5-point Likert-type scales. Items included: ÒFor me to take regular medication in 11	
the future isÉÓ (1: difficult to 5: easy) and ÒIt is up to me to take regular medicationÉÓ(1: 12	
strongly disagree to 5: strongly agree) [26].The measure of PBC proved internally consistent in 13	
this study (CronbachÕs α=0.93).
 
14	
2.6.8 Self-monitoring  15	
 Self-monitoring was measured using three items on a scale that ranged from 1 (strongly 16	
disagree) to 5 (strongly agree). Each item consisted of a main sentence: ÒDuring the last month, I 17	
have consistently monitoredÉÓ with ending variations being: (a) ÒÉwhen to take 18	
medicationsÓ,(b)ÒÉhow often to take medicationsÓ, and (c)ÒÉhow to take medicationsÓ 19	
[27].The internal consistency of self-monitoringin the present study was acceptable (CronbachÕs 20	
α=0.82).
 
21	
2.6.9! Beliefs about medicines  22	
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PatientsÕ beliefs about medication were measured using the Beliefs about Medicines 1	
Questionnaire (BMQ). Although the BMQ has specific and general sections,only the specific 2	
section,which is thought to be associated with adherence, was used in the present study [26]. The 3	
BMQ-specific reflects beliefs in two domainsÐ necessity and concerns Ð and patients are asked 4	
torespond to statements reflecting each(e.g., ÒMy health in the future will depend on my 5	
medicationÓ [necessity] and ÒMy medication disrupts my lifeÓ [concerns]) on a 5-point Likert-6	
type scale (from 1: strongly disagree to 5: strongly agree). Scores on each domain can range 7	
from 5 and 25 with higher scoresrepresentingmore worryabout taking medicine. A study with an 8	
Iranian sample with diabetes used the Persian version of BMQ,andshowed 9	
satisfactorypsychometric properties [29]. The internal consistency of the BMQ-Necessity and 10	
BMQ-Concernsin the present study were CronbachÕs α = 0.83 and CronbachÕs α = 0.85, 11	
respectively.  12	
2.6.10 Brief Illness Perception Questionnaire  13	
 The Brief Illness Perception Questionnaire(BIPQ) consists of 9 items that assess illness 14	
perceptionsin the following areas: Identity, consequences, timeline, personal control, treatment 15	
control, concern, understanding, illness comprehensibility, and emotional representations [30]. 16	
Each item is rated on an 11-point Likert scale, where a higher score represents a higher level of 17	
illness perception. We used the total score (i.e., summing responses across each of the 9 items), 18	
which represents the degree to which the illness is perceived as threatening or benign [30].The 19	
internal consistency of the BIPQ in the present study was acceptable (CronbachÕs α = 0.86). 20	
2.6.11 Health related quality of life: Short-Form 36  21	
20 
	
 The Health related quality of life: Short-Form 36 (SF-36) includes 36 items, measuring 1	
bothphysical (PCS; sample item: ÒIn general, would you say your health isÉÓ) and mental 2	
(MCS; sample item: ÒHave you felt calm and peaceful?Ó) health. The scores were converted into 3	
a 0-100 scale, with higher scores indicating better QoL [37,38]. The SF-36 has been translated 4	
into Persian and has been validated in a sample of Iranian hemodialysis patients showing 5	
satisfactory psychometric properties [39]. The internal consistencies of SF-36 subscales in the 6	
present study were acceptable and ranged from CronbachÕs α = 0.74 to CronbachÕs α = 0.93. 7	
2.7 Statistical Analysis  8	
Background information, clinical characteristics, and all outcome measuresare described 9	
using means and standard deviations (SD) for continuous variables and frequency and/or 10	
percentages (%) for categorical variables. Multilevel linear mixed modelswere used to 11	
investigate the efficacy of the intervention taking into account the hierarchical nature of the data 12	
(i.e., that the patients were clustered in different centers) and repeated measures (i.e., that a 13	
number of outcomes were measured at several time points). Intention to treat (ITT) analysis was 14	
used, such that outcomes among all patients allocated to the groups were analyzed, whether they 15	
completed the intervention or not.We used three levels of analysis (repeated measures as the 16	
first, patients as the second, and centers as the third levels) with a restricted iterative generalized 17	
least square (RIGLS) estimation. This RIGLS computesunbiased estimates of the random 18	
parameters. In addition, we used univariate multilevel analyses to investigate the effects of 19	
potential confounding variablesincluding age, education, family income, and body mass index. 20	
Confounding variables with a p value< 0.20 were controlled for in the multivariate models.As 21	
consequence, each model was adjusted for the following potential confounding variables: age, 22	
sex, Charlson comorbidity index, and body mass index.  23	
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Potential mediators of the relationship between the intervention and medication 1	
adherence and between the intervention and QoL were examined using Sobel tests. Finally, 2	
survival analyses accounting for cluster effects of the hospitals were performed, with the cluster 3	
effects of centers being adjusted.All tests were two-tailed using a significance level of <0.05. 4	
Benjamini and Hochberg false discovery rate was used to adjust p-values for multiple 5	
comparisons where appropriate. Multilevel linear mixed modelingwas conducted using MLwiN 6	
2.27 software. Survival analyses were performed usingthe survival package in R (R Core Team, 7	
2014). 8	
3. Results  9	
 After screening a total of 462 patients, 288 patients from 12 centers were eligible to 10	
participate in the study and the centers were randomly assignedto either the TAUor the 11	
EXPgroups(Figure 1).Thirty-five patients in the two groups dropped out during treatment.Table 12	
1 summarizes the baseline and clinical characteristics of the two groups. The mean age of 13	
patients in the TAU group was 75.23 (SD = 5.82) years and 74.32 (SD = 5.26) years for the EXP 14	
group and nearly two thirds of the patientswere male (65.3% in TAU and 67.4% in EXP).  15	
(Insert Table 1 here) 16	
 The descriptive statistics formedication adherence (including the MARS, objective 17	
pharmacy refill rate, and serum level of lipid profile), beliefs about medication, and QoL across 18	
the 18 months are reported in Table 2. Overall, patientsin the EXP groupshowed better 19	
medication adherence after six months compared to patientsin the TAU group, as indicated by 20	
the MARS (baseline: 7.68±2.45 in EXP and 7.62±2.76 in TAU; six months: 13.67±2.80 in EXP 21	
and 7.69 in TAU), pharmacy refill rate (baseline: 62.30±16.22%in EXP and 61.41±16.30% in 22	
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TAU; six months: 73.81±18.56% in EXP and 63.14±17.21% in TAU), HDL-C (baseline: 1	
34.54±9.89% in EXP and 34.42±9.74% in TAU; six months: 42.74±10.41% in EXP and 2	
34.18±9.38% in TAU), and LDL-C (baseline: 113.75±33.06 mg/dLin EXP and 3	
115.20±32.76mg/dL in TAU; six months: 99.26±36.75 mg/dLin EXP and 110.01±35.78 4	
mg/dLin TAU). Furthermore, medication adherence did not decrease after eighteen months in the 5	
EXP group and patients in this group reported slightly better QoL, including PCS and MCS, than 6	
patients in the TAU group after six months. 7	
(Insert Table 2 here) 8	
 After considering multicenter and other potential confounding factors and effects, the 9	
three-level multiple linear regression models showed that patients in the EXP group had better 10	
medication adherence after six, twelve, and eighteen months compared to patients in the TAU 11	
group (see Table 3) as indicated by the MARS (B = 3.97 at six months, 3.83 at twelve months, 12	
and 4.24 at eighteen months; p< 0.01), pharmacy refill rate (B = 9.82% at six months, 10.64% at 13	
twelve months, and 10.40% at eighteen months; p < 0.01), total cholesterol (B = -7.40 mg/dL at 14	
six months, -8.77mg/dL at twelve months, and -8.60 mg/dL at eighteen months; p < 0.01), LDL-15	
C (B= -12.45 mg/dL at six months, -13.71 mg/dL at twelve months, and -13.59 mg/dL at 16	
eighteen months; p < 0.01), HDL-C (B = 8.41 mg/dL at six months, 8.71mg/dL at twelve 17	
months, and 8.87 mg/dL at eighteen months; p < 0.01), and triglycerides (B = -16.83 mg/dL at 18	
six months, -18.86mg/dL at twelve months, and -18.21 mg/dL at eighteen months; p < 0.01). 19	
(Insert Table 3 here) 20	
 About 11.1% of the patients in the TAU group and 4.2% of the patients in the EXP group 21	
had died before theend of follow-up (Figure 2). When considering the loss at follow-up and 22	
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drop-outs, a Gamma frailty survival model on the time of death showed that the crude hazard 1	
ratio (HR) in the EXP compared to the TAU group was 0.36 (95% CI: 0.14 to 0.91, p=0.036). 2	
After adjusting for the effects of age, sex, and number of diseased vessels, this hazard 3	
ratiocontinued to show a lower rate of death in the EXP group compared to the TAU group 4	
(adjusted HR = 0.38, 95% CI: 0.15to 0.97, p=0.044). 5	
(Insert Figure 2 here) 6	
Electronic Supplementary Material Tables S3 and S4 show the effects of intervention on 7	
intentions, perceived behavioral automaticity, self-monitoring, action and coping planning, 8	
beliefs about medicines, illness perceptions, and QoL. Patients in the EXP group reported better 9	
QoL than did patients in the TAU group after eighteen months (B = 1.77 and p = 0.02 for PCS; B 10	
= 1.68 and p = 0.04 for MCS). The interactions between group and time tended to be significant 11	
such that patients in the EXP group (relative to those in the TAU group) tended to have more 12	
positive beliefs about taking medication, reported stronger intentions to take medication, and had 13	
perceptions of increased control over medication use. They were also more likely to have formed 14	
action and coping plans to support medication adherence and self-monitor their medication use; 15	
and reported that taking medication had become relatively automatic for them.Social cognitions 16	
and self-regulatory processes all mediated the effects of the intervention on mediation adherence 17	
(See Electronic Supplementary Material Table S5). An additional mediation analysis showed that 18	
medication adherence mediated the effects of the intervention on outcomes such as QoL and 19	
survival rates.  20	
4. Discussion 21	
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 The present findings suggest that a multifaceted intervention with three components 1	
(psycho-education, motivational interviewing [or MI], and SMS reminders) can improve 2	
medication adherence, QoL, and mortality ratesamong olderpatients undergoing CABGsurgery. 3	
Specifically, patients who received the multifaceted intervention program (i.e., patients in the 4	
EXP group) showed increased MARS scores and higher pharmacy refill rates six- and eighteen-5	
months post-surgery. In contrast, MARS scores and pharmacy refill ratesdid not increase among 6	
patients who received conventional treatment and information (i.e., among patients in the TAU 7	
group). Othermeasures used to objectively assess medication adherence (including total 8	
cholesterol, HDL-C, TDL-C, and triglycerides) supported these conclusions and showed that 9	
patients in the EXP group were in betterphysiological health than were patients in the TAU 10	
group in the six to eighteen month after the intervention. In addition to medication adherence, 11	
patients who received themultifaceted intervention also reported betterQoL andhad a higher life 12	
expectancy compared to patients in the TAU group.  13	
Previous studies have also reported beneficial effects of MI on medication adherence, 14	
albeit among different samples than those studied here, such as older people (aged 53-73 years) 15	
[40] and people with epilepsy [26].Furthermore, previous studies attest to the efficacy of 16	
combining medical counseling with planning for promoting medication adherence among 17	
patients undergoing CABG [18]. However, although a number of studies have shown the 18	
beneficial effects of such interventions, the current study combined the intervention components 19	
and, perhaps as a result, seemed to be even more effective in increasing medication adherence in 20	
older patients (d =2.13 in the present research; d = 0.30 to 1.02 in previous studies [18, 26, 40]). 21	
In short, the present findingssupport the effects of similar interventionsconducted in 22	
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otherpopulations [21,26,40],such as patients with epilepsy, and show that MI andcounseling can 1	
effectively enhance medication adherence in older individuals [41-44]. 2	
The present research also builds on previous studies by showing that a multifaceted 3	
intervention not only increases medication adherence but, as a result, can improveQoL and 4	
increaselife expectancy in olderpatients receiving CABG. Interestingly, theeffects on QoLwere 5	
only observed at eighteenmonths post-surgery,compared to the changes in medication 6	
adherence,which were observed at sixmonths after surgery.However, this is to be expected given 7	
that both previous and the present research show that QoL is influenced by medication adherence 8	
and thus takes time to change [45-47]. In terms of the effects of the intervention on survival 9	
rates, previous studies have demonstrated that psycho-education and MI can reduce mortality in 10	
patients with different diseases [48-50],including coronary heart disease patients. Our results 11	
echo suchfindings andfurthersupport the idea that the combination of psycho-education and MI 12	
can improve survival rates through medication adherence.  13	
4.1 Strengths and limitations 14	
There are several strengths to our study. First, an eighteen-month follow-up without 15	
further intervention was used to investigate the long-term effects of the intervention on 16	
medication adherence and a number of health-related outcomes in patients undergoing CABG. 17	
As such, the findingsprovide important insights for clinicians in regards to the long-term effects 18	
of such interventions, not only on medication adherence but also on patientsÕ overall health and 19	
QoL. Second, the present study included a variety of objective outcome measures to assess 20	
medication adherence and did not rely on self-report alone; therefore minimizing social 21	
desirability and reporting biases. Third, robust statistical analyses were conducted that accounted 22	
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for potential confounding variables. By using multilevel linear mixed models,shared variance 1	
(e.g., accruing from recruiting patients from the same hospital) were minimized [51].  2	
 However, there are also some limitations that need to be considered when interpreting the 3	
findings. First, the effects of the intervention may not be generalizable to Western countries and 4	
cultures, particularly asthe present researchincorporated an element of family engagement. 5	
Unlike Western cultures thattend to emphasizeindividualism [52],family plays a crucial role for 6	
people with a Middle Eastern cultural background [53].Second, patients with serious and/or 7	
specific health conditions (e.g., suffering from cognitive impairment or froma severe kidney 8	
disease) were excluded from the present research. Therefore, the findings may not generalizeto 9	
other patients undergoing CABG who have additional health problems. Further studies are 10	
therefore warranted to investigate the effects of similar interventions in such groups. Third, 11	
because the present research developed and implemented amultifaceted intervention, the 12	
individual effects of each component cannot be separated. In other words, it is unclear which of 13	
the three components (psycho-education, MI, and SMS reminders) were effective in promoting 14	
medication adherence, and could potentially be used as individual components, or whether the 15	
outcomes were dependent on a joint effect. The larger effect size reported in the present research, 16	
relative to other studies that tested the effects of interventions that only incorporated one or some 17	
of these components suggest that the multifaceted intervention was particularly beneficial, but 18	
factorial designs that directly compare interventions with different components are needed 19	
corroborate this assertion. Lastly, the intervention used in the present research was relatively 20	
intensive and required a substantial time commitment from both the patients and those delivering 21	
the intervention. Although the findings were promising, further research could evaluate the cost-22	
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effectiveness of the intervention relative to, for example, less complex interventions. Again, a 1	
factorial design would appear to be appropriate for this purpose. 2	
5. Conclusion 3	
 In conclusion, the findings of the present study suggest that a multifaceted intervention 4	
consisting ofpsycho-educational, MI, and SMS reminders can promote medication adherence in 5	
older patients undergoing CABG, and that these effects are maintained eighteenmonths post-6	
surgery. The increase in medication adherence as a function of the intervention also improved 7	
other health-related outcomes. Clinicians may therefore consider using multifaceted 8	
interventions to improve health and survival rates in older patients undergoing CABG. 9	
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Figure Legends 
Fig. 1:Flow diagram for random assignment of patients in the study.MMSE = Mini Mental 
Status Examination; CABG = coronary artery bypass graft 
Fig. 2: Survival rates for patients in multifaceted intervention group (EXP) and those in 
treatment as usual group (TAU).  
 
Supplementary Materials Legends 
Electronic Supplementary Material TableS1:The procedure for Motivational interviewing 
(MI) sessions. 
Electronic Supplementary Material TableS2: MITI global measures, behavior counts, and 
summary scores. 
Electronic Supplementary Material TableS3: Three-level multiple linear regression models 
predicting intention, perceived behavioral control, behavioral automaticity, self-monitoring, 
action planning and coping planning. 
Electronic Supplementary Material TableS4: Three-level multiple linear regression models 
predicting beliefs about medicines, illness perceptions, and quality of life (QoL). 
Electronic Supplementary Material TableS5: Direct and mediated effects of group on 
medication adherence, quality of life (QoL) and survival rates. 
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Tables  
Table 1 
Comparison of clinical characteristics between the intervention (EXP) and treatment as usual (TAU) groups at baseline 
 Treatment as usual 
(n = 144) 
Intervention 
(n = 144) 
Age, years; median (IQR) 76 (70-80) 75 (69-79) 
Years of education; median (IQR) 4 (1-12) 4 (1-12) 
Household income, rialsa; median (IQR) 848.65 (453.40-1295.44) 893.06 (942.88-1286.88) 
Body mass index, kg/m2; mean±SD 28.84±5.57 28.64±4.03 
Marital status; n (%)   
Single 4 (2.8%) 6 (4.2%) 
Married  90 (62.5%) 92 (63.9%) 
Divorced/widowed  50 (34.7%) 46 (31.9%) 
Sex; n (%)   
Male 94 (65.3%) 97 (67.4%) 
Female 50 (34.7%) 47 (32.6%) 
Ejection fraction; mean±SD 45.23±6.12 44.82±7.02 
Cross clamp time, minutes; mean±SD 52.42±25.81 54.21±27.62 
Cardiopulmonary bypass duration time, minutes; mean±SD 96.68±39.42 97.92±40.35 
Cardiac risk factors; n (%)   
Diabetes mellitus 55 (38.2%) 52 (36.1%) 
Hypertension 107 (74.3%) 110 (76.4%) 
Dyslipidemia 61 (42.4%) 52 (36.1%) 
Myocardial infarction 86 (59.7%) 90 (62.5%) 
Chronic lung disease 17 (11.8%) 15 (10.4%) 
Prior cardiac surgery; n (%) 12 (8.3%) 9 (6.2%) 
Current smoker; n (%) 21 (14.6%) 18 (12.5%) 
No. of major vessels/branches bypassed; n (%)   
1 vessel 21 (14.6%) 14 (9.7%) 
2 vessels 49 (34.0%) 46 (31.9%) 
2	
	
3 vessels  74 (51.4%) 84 (58.3%) 
CCSC; n (%)   
I 12 (8.3%) 10 (6.9%) 
II 24 (16.7%) 15 (10.4%) 
III 48 (33.3%) 51 (35.4%) 
IV 60 (41.7%) 68 (47.2%) 
Charlson comorbidity index; n (%)   
0 40 (27.8%) 36 (25.0%) 
1-3 79 (54.9%) 81 (56.2%) 
≥4 25 (17.4%) 27 (18.8%) 
Medications; n (%)   
Aspirin  135 (93.8%) 132 (91.7%) 
Beta blockers 115 (79.9%) 122 (84.7%) 
Angiotensin converting enzyme inhibitors 98 (68.1%) 90 (62.5%) 
Lipid lowering  105 (72.9%) 109 (75.7%) 
Number of centers  6 6 
Number of patients in each center 24 24 
Note. IQR = interquartile range, SD = standard deviation, CCSC: Canadian Cardiovascular Society Classification 
a 3,500 rials = US $1 (April 2016)
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Table 2 
Descriptive statistics for all outcome measures across time in the intervention group (EXP) and the treatment as usual (TAU) group 
Variable (normal range) Group 
Mean (SD) 
Baseline Month 6 Month 12 Month 18 
BMQ-Necessity (5-25) 
TAU 14.62 (3.22) 14.54 (3.30) 14.41 (2.42) 14.40 (3.07) 
EXP 14.37 (2.24) 18.69 (2.49) 18.64 (2.48) 18.53 (2.57) 
BMQ-Concerns (5-25) 
TAU 13.23 (4.05) 13.27 (4.0) 13.31 (4.27) 13.33 (4.12) 
EXP 12.92 (3.29) 7.81 (3.22) 6.02 (3.09) 4.78 (3.01) 
Perceived behavioral control (1-5) 
TAU 2.50 (0.93) 2.43 (0.98) 2.41 (0.99) 2.40  (0.93) 
EXP 2.49 (0.89) 3.00 (1.10) 2.98 (1.01) 2.99 (1.12) 
Intention (1-5) 
TAU 2.67 (0.65) 2.73  (0.69) 2.70 (0.70) 2.69 (0.69) 
EXP 2.72 (0.74) 3.44 (1.03) 3.41 (1.01) 3.42 (1.13) 
Self-monitoring (1-5) 
TAU 1.94 (0.40) 1.92 (0.51) 1.96 (0.75) 1.91 (0.82) 
EXP 2.06 (0.54) 2.65 (1.00) 2.67 (1.04) 2.66 (1.02) 
Action planning (1-5) 
TAU 1.93 (0.58) 1.190 (0.52) 1.88 (0.50) 1.86 (0.61) 
EXP 1.88 (0.57) 2.73  (1.13) 2.71 (1.30) 2.74 (1.29) 
Coping planning (1-5) 
TAU 1.68 (0.51) 1.64 (0.56) 1.61 (0.52) 1.62 (0.60) 
EXP 1.64 (0.54) 2.49 (1.11) 2.48 (1.19) 2.50 (1.26) 
Self-report Behavioral Automaticity Index (1-5) 
TAU 1.91 (0.80) 1.87 (0.82) 1.86 (0.99) 1.83 (1.01) 
EXP 1.86 (0.87) 2.39 (0.94) 2.40 (0.98) 2.40 (1.14) 
MARS (5-25) 
TAU 7.62 (2.76) 7.69 (2.70) 7.71 (2.79) 7.63 (2.88) 
EXP 7.68 (2.45) 13.67 (2.80) 13.61 (2.82) 13.70 (2.75) 
Illness perception (0-90) 
TAU 36.43 (11.67) 35.57 (11.66) 36.63 (11.54) 36.67 (11.47) 
EXP 37.07 (11.78) 33.93 (12.53) 33.80 (12.72) 33.46 (10.17) 
Pharmacy refill rate (0-100) 
TAU 61.41 (16.30) 63.14 (17.21) 62.03 (18.77) 62.03 (18.77) 
EXP 62.30 (16.22) 73.81 (18.56) 73.48 (18.44) 73.24 (15.33) 
Quality of life: PCS (0-100) 
TAU 46.07 (11.66) 48.23 (11.70) 47.88 (12.05) 47.08 (10.10) 
EXP 46.88 (10.68) 50.04 (12.41) 50.29 (12.69) 49.93 (9.65) 
Quality of life: MCS (0-100) 
TAU 43.42 (12.76) 46.77 (11.41) 46.82 (11.33) 46.48 (10.35) 
EXP 44.92 (10.14) 49.39 (12.60) 49.76 (10.93) 49.69 (11.84) 
Total cholesterol concentration (mg/dL) 
TAU 182.90 (38.69) 180.76 (33.89) 180.71 (33.51) 180.53 (35.81) 
EXP 181.85 (39.00) 172.32 (40.71) 170.92 (32.12) 171 (32.00) 
4	
	
HDL-C (mg/dL) 
TAU 34.42 (9.74) 34.18 (9.38) 33.88 (10.52) 33.52 (8.16) 
EXP 34.54 (9.89) 42.74 (10.41) 42.63 (11.29) 42.41 (9.31) 
LDL-C (mg/dL) 
TAU 115.20 (32.76) 110.01 (35.78) 113.32 (35.57) 114.51 (35.65) 
EXP 113.75 (33.06) 99.26 (36.75) 98.26 (27.32) 98.69 (27.41) 
Triglycerides (mg/dL) 
TAU  166.37 (66.60) 167.07 (65.99) 167.52 (55.43) 165.27 (65.21) 
EXP 167.61 (69.38) 151.55 (66.55) 150.13 (58.05) 149.33 (68.90) 
Note. BMQ= Beliefs about Medicines Questionnaire; MARS= Medication Adherence Rating Scale; PCS= Physical Component Summary; MCS= 
Mental Component Summary; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol 
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Table 3 
Three-level multiple linear regression models predicting medication adherence 
Variable  MARS Pharmacy refill rate Total cholesterol LDL-C HDL-C Triglycerides 
 Β (SE) 
p 
value 
Β (SE) p value Β (SE) p value Β (SE) 
p 
value 
Β (SE) 
p 
value 
Β (SE) 
p 
value 
Group (Ref: TAU) 
0.30 
(0.66) 
0.36 
2.37 
(2.62) 
0.26 
-3.30 
(7.25) 
0.36 
-3.01 
(5.94) 
0.35 
15.52 
(5.64) 
0.01 
-4.54 
(9.73) 
0.36 
Time (Ref: baseline)              
6 months 
0.38 
(0.16) 
0.02 
1.81 
(0.66) 
0.01 
-2.21 
(1.34) 
0.10 
-2.22 
(1.29) 
0.09 
0.12 
(0.43) 
0.38 
-0.61 
(1.79) 
0.38 
12 months 
0.30 
(0.14) 
0.045 
0.66 
(0.46) 
0.14 
-2.26 
(1.60) 
0.15 
-1.97 
(1.31) 
0.13 
0.54 
(0.40) 
0.16 
-1.21 
(1.94) 
0.33 
18 months 
0.05 
(0.16) 
0.38 
0.91 
(0.78) 
0.20 
-2.45 
(1.60) 
0.12 
-1.79 
(1.30) 
0.16 
0.92 
(0.31) 
0.01 
-1.38 
(1.86) 
0.30 
Group×time             
EXP vs. TAU at 6 months 
3.97 
(0.22) 
<0.01 
9.82 
(0.93) 
<0.01 
-7.40 
(1.88) 
<0.01 
-12.45 
(1.80) 
<0.01 
8.41 
(0.60) 
<0.01 
-16.83 
(2.52) 
<0.01 
EXP vs. TAU at 12 months 
3.83 
(0.23) 
<0.01 
10.64 
(0.95) 
<0.01 
-8.77 
(1.92) 
<0.01 
-13.71 
(1.93) 
<0.01 
8.71 
(0.73) 
<0.01 
-18.86 
(2.80) 
<0.01 
EXP vs. TAU at 18 months 
4.24 
(0.26) 
<0.01 
10.40 
(0.98) 
<0.01 
-8.60 
(1.99) 
<0.01 
-13.59 
(1.78) 
<0.01 
8.87 
(0.60) 
<0.01 
-18.21 
(2.70) 
<0.01 
Age 
-0.19 
(0.14) 
0.17 
-0.13 
(0.13) 
0.25 
1.40 
(1.41) 
0.24 
0.61 
(1.23) 
0.35 
-0.92 
(0.35) 
0.01 
0.46 
(1.91) 
0.39 
Sex (Ref: females) 
0.33 
(0.47) 
0.31 
-8.32 
(2.58) 
<0.01 
2.52 
(1.63) 
0.12 
5.16 
(3.68) 
0.15 
0.12 
(0.10) 
0.20 
0.62 
(0.86) 
0.31 
Charlson comorbidity index 
-0.92 
(0.65) 
0.15 
-1.69 
(0.75) 
0.03 
9.59 
(7.22) 
0.17 
-11.85 
(6.91) 
0.09 
-6.64 
(1.49) 
<0.01 
2.28 
(0.98) 
0.03 
Body mass index 
-0.06 
(0.04) 
0.16 
-0.31 
(0.61) 
0.35 
3.26 
(1.26) 
0.01 
1.76 
(4.01) 
0.36 
-0.35 
(0.19) 
0.07 
8.37 
(0.91) 
<0.01 
Intercept 
11.14 
(2.32) 
<0.01 
55.19 
 (8.66) 
<0.01 
164.84 
(23.06) 
<0.01 
11.02 
(2.26) 
<0.01 
15.21 
(5.64) 
0.01 
187.83 
(45.75) 
<0.01 
σ
st
2
 (patients)  
14.97 
(0.96) 
<0.01 
103.90 
(13.19) 
<0.01 
46.70 
(9.18) 
<0.01 
53.59 
(8.41) 
<0.01 
93.12 
(5.98) 
<0.01 
46.91 
(15.61) 
<0.01 
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σ
sc
2
 (centers)  
3.52 
(0.12) 
<0.01 
32.08 
(11.64) 
0.01 
26.23 
(8.58) 
<0.01 
37.21 
(6.81) 
<0.01 
9.49 
(3.88) 
0.02 
24.92 
(16.10) 
0.12 
Note. Ref. = reference group for comparison; TAU=treatment as usual group; EXP= intervention group; MARS= Medication Adherence Rating 
Scale; LDL-C= low-density lipoprotein cholesterol; HDL-C= high-density lipoprotein cholesterol; σ
st
2
 = the variance at patient level; σ
sc
2
 = the 
variance at center level; SE = standard error. 
p values < 0.05 are in bold 
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Electronic Supplementary Material Table S1. The procedure for motivational 
interviewing (MI) sessions. 
First 
session 
The facilitator introduced himself/herself to the patients and assured them that 
the conversations would be kept private. The facilitators then elicited problems 
that the patients faced by asking questions such as ÒHow do you describe your 
problem?Ó; ÒWhat do you think has caused your problem?Ó; ÒWhat do you fear 
most about your illness?Ó. Patients had the chance to describe their condition(s) 
and talk about their concerns with the facilitator. The facilitators further 
encouraged the patients to discuss any concerns that may interfere with their 
willingness and/or motivation to adhere to their medication. Facilitators also 
provided specific information on the medication that patients were asked to take 
(e.g., dosage and timing, adverse effects, contradictions, and treatment process). 
Second 
session 
The patients were encouraged to talk about their feelings regarding their 
condition and medication adherence. Open ended questions, including ÒHow 
have things gone this week?Ó and ÒHow have you been feeling?Ó were used to 
assess the patientÕs feelings during the past week (e.g., feelings about new 
stressors, changes in condition, etc.). Facilitators also inquired about the 
patientsÕ adherence and their reaction to the medication to obtain an overall 
impression of the emotional experiences of the patients. 
Third 
session 
The third session focused on helping the patients to evaluate the perceived costs 
and benefits of medication adherence. The goal was to identify the positive and 
negative consequences of taking medication, (e.g., ÒWhat do you see as the 
positive and negative consequences of taking medication?Ó and ÒWhat are some 
of the long-term and short-term effects of regularly taking your medication?Ó). 
Alternative courses of action were also considered during this session. For 
example, patients were encouraged to think about what the future would look 
like if they adhered to their medication. Questions to illicit these thoughts were 
e.g. ÒIf you are successful in regularly taking medicine, how could things be 
different in the future?Ó, or ÒWhat will be the impact on your quality of life?Ó. 
Fourth 
session 
The fourth session focused on the patientsÕ values and goals. The facilitators 
assisted the patients in recognizing and attaining their values and goals by 
encouraging them to engage in confidence talk to increase their motivation for 
medication adherence. 
Fifth 
session 
The facilitators helped the patients to review their progress, reinforce their 
motivation and recognize their success in adherence. Following this, the patients 
were advised to keep a daily diary and to note the frequency of the medications 
that they have to take. The facilitators also encouraged the patients to form 
specific plans and identify strategies that would help them to take their 
medication (i.e., action planning). They were then asked to imagine themselves 
in this specific situation and evaluate how their strategies might help them to 
remember to take their medication. The patients wrote their plans on a form and 
were encouraged to sign it and consider it as a contract. 
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Electronic Supplementary Table S2. MITI global measures, behavior counts and summary scores. 
Measurers Mean ±SD 
(n=140) 
Minimum Maximum Beginning 
proficiency 
Competency 
Global measures      
Evocation 4.12 (0.72) 1 5   
Collaboration 3.61 (0.51) 1 5   
Autonomy/support 3.98 (0.58) 1 5   
Direction 4.23 (0.67) 1 5   
Empathy  4.59(0.71) 1 5   
Behavior counts      
Giving information 0.65 (0.39) 0 6   
MI-Adherent 7.93 (3.12) 0 25   
MI-Non-adherent 1.02 (0.93) 0 5   
Closed questions 12.39 (8.65) 0 38   
Open questions 18.81 (4.43) 0 41   
Simple reflections 16.28 (9.10) 0 61   
Complex reflections 12.02 (6.12) 1 35   
Summary scores      
Global spirit rating 3.93(0.52) 1.97 4.95 3.5 4 
Percentage of complex 
reflections 
47.69 (12.88) 10.00 100.00 40% 50% 
Percentage of open 
questions 
62.57(16.34) 25.39 100.00 50% 70% 
Reflection-to- 
question ratio 
1.05 (2.13) 0.31 16.35 1 2 
Percentage MI-Adherent 93.12(8.20) 61.08 100.00 90% 100% 
Note. MITI= Motivational Interviewing Treatment Integrity; MI=motivational interviewing 
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Electronic Supplementary Material Table S3. Three-level multiple linear regression models predicting intention, perceived behavioral 
control, behavioral automaticity, self-monitoring, action planning and coping planning. 
Variable  INT PBC SRBAI SM AP CP 
 Β (SE) p value Β (SE) 
p 
value 
Β (SE) 
p 
value 
Β (SE) 
p 
value 
Β (SE) 
p 
value 
Β (SE) 
p 
value 
Group (Ref: TAU) 
0.06 
(0.12) 
0.35 
0.12 
(0.18) 
0.32 
0.02 
(0.08) 
0.38 
0.09 
(0.15) 
0.34 
0.14 
(0.13) 
0.21 
0.14 
(0.12) 
0.20 
Time (Ref: baseline)              
6 months 
0.06 
(0.04) 
0.13 
0.06 
(0.04) 
0.11 
0.04 
(0.04) 
0.22 
0.02 
(0.02) 
0.24 
0.01 
(0.03) 
0.37 
0.02 
(0.05) 
0.37 
12 months 
0.03 
(0.03) 
0.30 
0.08 
(0.02) 
<0.01 
0.04 
(0.03) 
0.15 
0.06 
(0.05) 
0.21 
0.04 
(0.05) 
0.28 
0.05 
(0.04) 
0.21 
18 months 
0.02 
(0.03) 
0.34 
0.10 
(0.04) 
0.01 
0.09 
(0.04) 
0.051 
0.08 
(0.04) 
0.049 
0.06 
(0.05) 
0.18 
0.07 
(0.08) 
0.28 
group × time             
EXP vs. TAU at 6 
months 
0.61 
(0.05) 
<0.01 
0.58 
(0.05) 
<0.01 
0.57 
(0.05) 
<0.01 
0.54 
(0.06) 
<0.01 
0.84 
(0.06) 
<0.01 
0.85 
(0.07) 
<0.01 
EXP vs. TAU at 12 
months 
0.61 
(0.06) 
<0.01 
0.57 
(0.06) 
<0.01 
0.47 
(0.06) 
<0.01 
0.54 
(0.06) 
<0.01 
0.87 
(0.07) 
<0.01 
0.87 
(0.06) 
<0.01 
EXP vs. TAU at 18 
months 
0.63 
(0.05) 
<0.01 
0.61 
(0.06) 
<0.01 
0.50 
(0.06) 
<0.01 
0.58 
(0.06) 
<0.01 
0.93 
(0.07) 
<0.01 
0.95 
(0.08) 
<0.01 
2	
	
Age 
-0.03 
(0.02) 
<0.01 
0.01 
(0.03) 
0.38 
0.03 
(0.03) 
0.25 
-0.04 
(0.02) 
0.07 
-0.02 
(0.03) 
0.28 
-0.03 
(0.03) 
0.27 
Sex (Ref: females) 
-0.11 
(0.09) 
0.17 
0.21 
(0.20) 
0.23 
0.03 
(0.02) 
0.14 
-0.28 
(0.15) 
0.07 
-0.17 
(0.10) 
0.09 
-0.16 
(0.09) 
0.09 
Charlson comorbidity 
index 
-0.35 
(0.12) 
<0.01 
-0.30 
(0.08) 
<0.01 
-0.09 
(0.02) 
<0.01 
-0.20 
(0.10) 
0.06 
-0.47 
(0.13) 
<0.01 
-0.46 
(0.14) 
<0.01 
Body mass index  
0.05 
(0.08) 
0.34 
-0.054 
(0.10) 
0.59 
-0.03 
(0.05) 
0.34 
-0.01 
(0.07) 
0.39 
-0.05 
(0.09) 
0.33 
-0.05 
(0.93) 
0.40 
Intercept 
3.27 
(0.42) 
<0.01 
2.49 
(0.52) 
<0.01 
2.20 
(0.49) 
<0.01 
2.86 
(0.38) 
<0.01 
2.60 
(0.47) 
<0.01 
2.37 
(0.49) 
<0.01 
σ
st
2
 (patients)  
0.50 
(0.03) 
<0.01 
0.67 
(0.04) 
<0.01 
0.61 
(0.04) 
<0.01 
0.30 
(0.02) 
<0.01 
0.58 
(0.04) 
<0.01 
0.58 
(0.04) 
<0.01 
�
��
2
 (centers)  
0.06 
(0.02) 
0.02 
0.22 
(0.07) 
<0.01 
0.17 
(0.05) 
<0.01 
0.13 
(0.04) 
<0.01 
0.09 
(0.03) 
0.01 
0.09 
(0.03) 
0.01 
Note. Ref. = reference group for comparison; TAU = treatment as usual group; EXP = intervention group; INT = intention. PBC = Perceived behavioral 
control; SRBAI = Self-report Behavioral Automaticity Index; SM = Self-monitoring; AP = Action planning; CP = Coping planning; σ
st
2
 = the variance at 
patient level; �
��
2
 = the variance at center level; SE = standard error. 
p-values< 0.05 are in bold 
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Electronic Supplementary Material Table S4. Three-level multiple linear regression models predicting beliefs about medicines, illness 
perceptions, and quality of life (QoL). 
Variable  BMQ-Necessity BMQ-Concerns Illness perceptions QoL: PCS QoL: MCS 
 Β (SE) p value Β (SE) p value Β (SE) p value Β (SE) p value Β (SE) 
p 
value 
Group (Ref: TAU) 0.35 (0.70) 0.35 -0.24 (0.66) 0.37 
-0.17 
(1.54) 
0.40 
1.11 
(1.95) 
0.34 
1.55 
(1.73) 
0.27 
Time (Ref: baseline)            
6 months 0.08 (0.12) 0.33 -0.35 (0.16) 0.03 
-0.14 
(0.31) 
0.36 
2.27 
(0.52) 
<0.01 
3.50 
(0.64) 
<0.01 
12 months 0.63 (0.12) <0.01 -0.21 (0.15) 0.16 
-0.21 
(0.13) 
0.11 
2.14 
(0.50) 
<0.01 
3.12 
(0.80) 
<0.01 
18 months 0.66 (0.13) <0.01 -0.30 (0.16) 0.06 
0.25  
(0.35) 
0.31 
1.30 
(0.50) 
0.01 
3.15 
(0.93) 
<0.01 
group × time           
EXP vs. TAU at 6th month 4.27 (0.17) <0.01 -7.40 (0.22) <0.01 
-3.31 
(0.43) 
<0.01 
0.92 
(0.70) 
0.17 
1.02 
(0.90) 
0.21 
EXP vs. TAU at 12th month 4.77 (0.17) <0.01 -7.88 (0.24) <0.01 
-3.52 
(0.47) 
<0.01 
1.23 
(0.62) 
0.055 
1.40 
(0.96) 
0.14 
EXP vs. TAU at 18th month 4.82 (0.18) <0.01 -7.81 (0.23) <0.01 
-3.91 
(0.50) 
<0.01 
1.77 
(0.73) 
0.02 
1.68 
(0.80) 
0.04 
Age 
-0.08 
(0.70) 
0.40 
0.09  
(0.11) 
0.28 
0.22  
(0.31) 
0.31 
-0.50 
(0.69) 
0.31 
-0.271 
(0.61) 
0.66 
Sex (Ref: females) 
-0.75 
(0.70) 
0.22 
1.50  
(0.65) 
0.03 
3.26  
(2.54) 
0.17 
0.13 
(0.21) 
0.33 
3.67 
(2.72) 
0.16 
Charlson index 
-0.14 
(0.11) 
0.18 
0.05  
(0.35) 
0.39 
0.50  
(0.12) 
<0.01 
-1.82 
(1.39) 
0.17 
-1.61 
(1.78) 
0.27 
Body mass index 
-0.12 
(0.20) 
0.34 
0.07  
(0.32) 
0.39 
0.24  
(0.31) 
0.30 
-1.11 
(1.21) 
0.26 
-0.04 
(0.87) 
0.40 
Intercept 
16.34 
(1.58) 
<0.01 10.96 (1.79) <0.01 
41.88 
 (6.77) 
<0.01 
33.56 
(10.62) 
<0.01 
46.12 
(12.96) 
<0.01 
σ
st
2
 (patients)  5.50 (0.36) <0.01 
7.66  
(0.51) 
<0.01 
117.04 
(7.24) 
<0.01 
43.76 
 (2.70) 
<0.01 
58.14 
 (1.98) 
<0.01 
2	
	
�
��
2
 (centers)  2.21 (0.08) <0.01 
3.54  
(0.12) 
<0.01 
13.70 
(0.46) 
<0.01 
33.43 
(1.17) 
<0.01 
17.96 
(2.57) 
<0.01 
Note. Ref. = reference group for comparison; TAU = treatment as usual group; EXP = intervention group; BMQ = Beliefs about Medicines Questionnaire; 
PCS = Physical Component Summary; MCS = Mental Component Summary; σ
st
2
 = the variance at patient level; �
��
2
 = the variance at center level; SE = 
standard error. 
p values < 0.05 are in bold 
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Electronic Supplementary Material Table S5. Direct and mediated effects of group on medication adherence, quality of life (QoL) and 
survival rates. 
Outcome Time 
(months) 
Mediator Coefficient (SE) 
A. Intervention 
effect on outcome  
B. Intervention effect 
on mediator 
C. Mediator effect 
on outcome 
Mediated effect 
(=B
*
C) 
Medication 
adherence 
6  3.97 (0.22)**    
BMQ-Necessity  4.27 (0.17)** 0.32 (0.03)** 1.37 (0.14)** 
BMQ-Concerns  -7.40 (0.22)** -0.27 (0.02)** 2.00 (0.16)** 
PBC  0.58 (0.05)** 0.66 (0.10)** 0.38 (0.07)** 
Intention  0.61 (0.05)** 0.85 (0.12)** 0.52 (0.08)** 
Self monitoring  0.54 (0.06)** 1.22 (0.11)** 0.66 (0.09)** 
Action planning  0.84 (0.06)** 0.95 (0.10)** 0.80 (0.10)** 
Coping planning  0.85 (0.07)** 0.95 (0.10)** 0.81 (0.11)** 
SRBIA  0.57 (0.05)** 0.22 (0.10)* 0.12 (0.06)* 
12  3.83 (0.23)**    
BMQ-Necessity  4.77 (0.17)** 0.25 (0.03)** 1.19 (0.15)** 
BMQ-Concerns  -7.88 (0.24)** -0.29 (0.04)** 2.29 (0.33)** 
PBC  0.57 (0.06)** 0.61 (0.11)** 0.35 (0.07)** 
Intention  0.61 (0.06)** 0.88 (0.11)** 0.54 (0.08)** 
Self monitoring  0.54 (0.06)** 1.20 (0.13)** 0.65 (0.10)** 
Action planning  0.87 (0.07)** 0.98 (0.11)** 0.85 (0.12)** 
Coping planning  0.87 (0.06)** 0.96 (0.09)** 0.83 (0.10)** 
SRBIA  0.47 (0.06)** 0.14 (0.10) 0.06 (0.05) 
18  4.24 (0.26)**    
BMQ-Necessity  4.82 (0.18)** 0.26 (0.04)** 1.25 (0.20)** 
BMQ-Concerns  -7.81 (0.23)** -0.31 (0.05)** 2.24 (0.40)** 
PBC  0.61 (0.06)** 0.60 (0.09)** 0.37 (0.06)** 
Intention  0.63 (0.05)** 0.92 (0.14)** 0.58 (0.10)** 
Self monitoring  0.58 (0.06)** 1.32 (0.14)** 0.77 (0.11)** 
Action planning  0.93 (0.07)** 0.96 (0.09)** 0.89 (0.11)** 
Coping planning  0.95 (0.08)** 0.93 (0.12)** 0.88 (0.14)** 
SRBIA  0.50 (0.06)** 0.16 (0.10) 0.10 (0.05)* 
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PCS 
6  0.92 (0.70)    
Medication adherence   3.97 (0.22)** 0.18 (0.05)** 0.71 (0.20)** 
Pharmacy refill rate  9.82 (0.93)** 0.07 (0.02)** 0.69 (0.21)** 
12  1.23 (0.062)    
Medication adherence  3.83 (0.23)** 0.160 (0.01)** 0.61 (0.05)** 
Pharmacy refill  10.64 (0.95)** 0.06 (0.02)** 0.64 (0.11)** 
18  1.77 (0.73)*    
Medication adherence  4.24 (0.26)** 0.102 (0.04)** 0.42 (0.17)* 
Pharmacy refill  10.40 (0.98)** 0.09 (0.03)** 0.94 (0.32)** 
MCS 
6  1.02 (0.90)    
Medication adherence  3.97 (0.22)** 0.28 (0.04)** 1.11 (0.17)** 
Pharmacy refill  9.82 (0.93)** 0.05 (0.01)** 0.49 (0.11)** 
12  1.40 (0.96)    
Medication adherence  3.83 (0.23)** 0.30 (0.06)** 1.15 (0.24)** 
Pharmacy refill  10.64 (0.95)** 0.06 (0.02)** 0.64 (0.22)** 
18  1.68 (0.80)*    
Medication adherence  4.24 (0.26)** 0.29 (0.05)** 1.23 (0.22)** 
Pharmacy refill  10.40 (0.98)** 0.04 (0.01)** 0.42 (0.11)** 
Survival 
rate 
6  1.92 (0.67)**    
Medication adherence  3.97 (0.22)** 0.06 (0.02)** 0.24 (0.08)** 
Pharmacy refill  9.82 (0.93)** 0.12 (0.04)** 1.18 (0.41)** 
12  2.14 (0.38)**    
Medication adherence  3.83 (0.23)** 0.08 (0.03)** 0.31 (0.11)** 
Pharmacy refill  10.64 (0.95)** 0.19 (0.03)** 2.02 (0.34)** 
18  2.87 (0.47)**    
Medication adherence  4.24 (0.26)** 0.07 (0.01)** 0.30 (0.05)** 
Pharmacy refill  10.40 (0.98)** 0.31 (0.11)** 3.22 (1.18)** 
BMQ= Beliefs about Medicines Questionnaire; PBC= Perceived behavioral control; SRBIA= Self-report Behavioral Automaticity Index; PCS = Physical 
Component Summary; MCS = Mental Component Summary; SE = standard error. 
*p < 0.05; **p < 0.01. 
